Retinal Degeneration clinical trials at UC Davis
1 research study open to eligible people
Study of the Effectiveness and Safety of Brolucizumab Compared to Aflibercept for Neovascular Age-related Macular Degeneration
open to eligible people ages 50 years and up
The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.
Sacramento, California and other locations